Pacira Pharma (PCRX) Tops Q4 EPS by 8c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/23/2026

1. ABBV
2. SPCX
3. MU
4. SPY
5. ACN
6. IBM
7. PRIM
8. PFE
9. TSLA
10. DPZ

Go back to Pacira Pharma (PCRX) Tops Q4 EPS by 8c

BofA/Merrill Lynch Downgrades Pacira Pharmaceuticals (PCRX) to Underperform

February 26, 2015 6:19 AM EST

BofA/Merrill Lynch downgraded Pacira Pharmaceuticals (NASDAQ: PCRX) from Neutral to Underperform with a price target of $110.00 (from $112.00).

Analyst Steve Byrne said high expectations are priced in, with more potential to miss than to exceed views.

The firm lowered FY 2015 EPS from... More

Pacira Pharmaceuticals (PCRX) PT Lifted to $136 at Piper Jaffray

February 25, 2015 9:49 AM EST

Piper Jaffray analyst David Amsellem reiterated an Overweight rating and bumped his price target on Pacira Pharmaceuticals (NASDAQ: PCRX) to $136.00 (from $134.00) following Q4 results yesterday.

Amsellem commented, "This morning, Pacira reported non-GAAP diluted EPS of $0.35, ahead of the Street estimate of $0.25, on Exparel sales of... More

Pacira Pharmaceuticals (PCRX) PT Lifted to $133 at Wedbush

February 25, 2015 6:57 AM EST

Wedbush analyst Liana Moussatos reiterated an Outperform rating and boosted her price target on Pacira Pharmaceuticals (NASDAQ: PCRX) to $133.00 (from $130.00) after preannounced Q4 EXPAREL sales and Q4 was 1st profitable quarter on GAAP basis.

Moussatos believe that the Street has overlooked the impact of EXPAREL's... More